Critical Path 2007 April 23-24, 2007 San Diego, CA The Critical Path Initiative is the U.S. Food and Drug Administration's response to what it sees as the drug development pipeline problem of increased costs and fewer safe and effective new medical products for patients. Register now for this conference and networking event taking place in the beautiful biotech hub of San Diego, CA. Stakeholders from industry, government and academia will engage in lively panel discussions on the latest news and present their research on Critical Path topics such as:         - The Future of the FDA's Critical Path Initiative         - Biomarkers and Toxicology         - Biomarkers and Imaging Technology         - Biomarkers and Cancer         - Improving Clinical Trials         - Bioinformatics and the Critical Path         - Nanotechnology in Drug Design & Manufacturing Register for this conference and take part in shaping 21st century medicine. Exhibiting, sponsoring and recruiting opportunities are currently available. SPEAKERS FDA - INVITED Dr. Jacques Demotes-Mainard, ECRIN, INSERM-DRCT Imaging Biomarkers in Drug Discovery and Development: an over-reaching strategy Giora Feuerstein, MD, Assistant Vice President, Head, Discovery Translational Medicine, WYETH RESEARCH Pathotropically Targeted Genetic Medicine: Critical Path to Highly Advanced Medical Technologies and Nanodevices Dr. Frederick L. Hall, President & CEO, EPEIUS BIOTECHNOLOGIES The role of Information Technologies in Biomarker Discovery and Development Michael Hehenberger, Ph.D., Solutions Executive, Life Sciences/Pharma Transformation, IBM GLOBAL INNOVATION, HEALTHCARE AND LIFE SCIENCES Discovery and validation of protein biomarkers for human oral cancer Shen Hu, Ph.D., Assistant Professor, Oral Biology and Proteomics and Member Dental Research Institute, UCLA Mitochondrial DNA as a Biomarker Dr. John P. Jakupciak, Biotechnology Division, NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY Addressing the Challenge of Organizing and Correlating Diverse High Throughput Date Types Dr. Keith Joho, Bioinformatics Consultant (Chair) Systems Biology through Integrative Genomics Andrew Kasarskis, Scientific Director, Genetics, ROSETTA INPHARMATICS LLC - MERCK RESEARCH LABORATORIES Strategic Medicine: A New Approach to Breast Cancer Michael N. Liebman, Executive Director, WINDBER RESEARCH INSTITUTE Front-Loaded BioOncology Drug Development: A Critical Path Opportunity Nelson L'ntshotshole Jumbe, Ph.D., BioOncology Modeling & Simulation, Dept. of Pharmacokinetics, Pharmacodynamics and Bioanalytical Assays, GENENTECH Personalized Medicine: How will it unfold? Linda McAllister, MD, PhD, Director, Technology Management, US Chief Technology Office, ROCHE DIAGNOSTICS Molecular Imaging in the Era of Molecular Medicine-Requirements for Clinical Practice Alexander J.B. (Sandy) McEwan, Director, Department of Oncologic Imaging, CROSS CANCER INSTITUTE Accelerating the Critical Path: Applications of in silico technologies to drug discovery and development Seth Michelson, Ph.D., Biomathematician, Modeling & Simulation (Chair) Validation, Standardization, Acceptance and the Utilization of Imaging in Phase I/II v Ph III studies Colin Miller, PhD FICR, SVP Medical Affairs, BIO-IMAGING TECHNOLOGIES INC. Nanotechnology for Cancer: Opportunities and Challenges Linda Molnar, PhD, Technical Program Manager, Center for Advanced Materials and Nanotechnology, NCI/NIH Gene-based Tests For Personalized Medicine Robert Morrison, PhD,, Principal, BIOINVENSION Dr. Damian O'Connell, Executive Director, Clinical R&D, PFIZER GLOBAL RESEARCH AND DEVELOPMENT William Ricketts, PhD, Vice President, Chief Scientific Officer, ONCOTECH INC. Alan H. Roter, VP, Informatics, ICONIX BIOSCIENCES, INC. Cyclodextrin-polymer nanoparticles: Enabling platform technology for chemotherapeutics Thomas Schluep, Chief Scientific Officer, INSERT THERAPEUTICS, INC. Patient enrichment using Systems Biology Birgit Schoeberl, PhD, Director, Network Biology, MERRIMACK PHARMACEUTICALS Experiences with dose finding in patients in early drug development: the use of biomarkers in early decision making. Dr. Stefan Sultana, MD, Senior Director & Translational Medicine Leader, GU, PFIZER Translational Biomarkers of Flux through Disease Pathways Scott Turner, PhD, Vice President, Operations, KINEMED, INC. Developing Theranostics: The diagnostic side of the equation Dr. Gunars Valkirs, Senior Vice President, Biosite Discovery, BIOSITE CONFERENCE CHAIRS Erlinda M. Gordon, MD, Vice President, Operations and Medical Affairs, Founder and Chairman of the Board, Epeius Biotechnologies Dr. Keith Joho, Bioinformatics Consultant Seth Michelson, PhD, Biomathematician, Modeling & Simulation VENUE The Dana on Mission Bay 1710 W. Mission Bay Dr. San Diego, CA 92109 Telephone: 619-222-6440 Fax: 619-222-4031 Special group rate available.

Copyright © Axon Intelligence Media, LLC. All rights reserved.